Colon Cancer - A Volunteer's Words
“I am confident that formula is helping. I know my body and how it reacts, and I know when the cancer is active or not. Since the drops, I have felt much better, and much less beset by tumor pain, which means less activity.”
Colon Cancer Patient (a 47-year-old man)
Colon Cancer Improvement Case Report
Novel Concepts Medical case study shows an improvement in a colon cancer patient with metastases in his liver, and a shrink in his tumor size after using our plant-based treatment. No side effects have been reported of our treatment.
It is known that approximately half of patients with colorectal cancer in the world, which includes colon cancer, develop metastases, and survival rates drop significantly among such patients.
This case study, as well as several others we performed, show that plant-based treatment may improve the medical condition of cancer patients.
[A] History
A 46 year old British patient was diagnosed with metastatic colon cancer with three liver metastases at the Royal Marsden hospital in London in July 2021.
Below is his diagnostic imaging report from July 15, 2021
The following are the patient’s blood test results before our treatment, from 08/07/2021 to 15/11/2021:
[B] Our Treatment of the Patient
- The patient received our exclusive plant-based treatment for a couple of weeks in July 2022 in the break between chemotherapy sessions, From 05/07/2022 through 20/07/2022.
- Following that time his blood tests confirmed that his liver biomarkers and blood test results improved and that his CEA cancer marker and C-reactive protein decreased.
- Our treatment also positively affected his appetite and energy. He was able to eat better, walk out of bed, and take a daily walk of a few miles during that period.
- The following are the relevant changes to his biomarkers (the full results of his blood tests can be viewed in the photo of the blood tests reports below:
| Biomarker (unit) | Normal Range | 05/07/2022 (before treatment) | 20/07/2022 (after treatment) |
|---|---|---|---|
| Liver Biomarkers | |||
| Creatinine (μmol/L) | 62-106 | 47 | 54 |
| Albumin (g/L) | 35-50 | 44 | 46 |
| Alkaline phosphatase (iu/L) | 30-130 | 83 | 86 |
| Bilirubin (μmol/L) | <21 | 7 | 9 |
| Total protein (g/L) | 60-80 | 64 | 68 |
| Globulin (g/L) | 20-40 | 20 | 22 |
| Other Biomarkers | |||
| Haemoglobin (g/L) | 130-170 | 125 | 142 |
| Lymphocytes (×10^9/L) | 1.0-3.0 | 0.7 | 0.8 |
| Haematocrit (L/L) | 0.400-0.500 | 0.388 | 0.437 |
| RBC (×10^12/L) | 4.5-5.5 | 3.9 | 4.5 |
| Creatinine (μmol/L) | 62-106 | 47 | 54 |
| C Reactive Protein | <5.0 | 10.8 | 4.3 |
| (HCA) – CEA (ng/mL) | <3.9 | 14 | 13 |
- After the period of our treatment and after an exam on 6/10/22 his medical report concluded “Overall essentially stable disease compared to the previous CT… with a marginal reduction in the size of the enlarged left supraclavicular node and left adrenal metastatic deposit. Stable disease elsewhere”
[C] The Patient’s Blood Tests Before and After Our Treatment
